Last update 20 Jun 2025

Baloxavir Marboxil

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Baloxavir, Baloxavir marboxil (JAN/USAN/INN), 巴洛沙韦酯
+ [9]
Target
Action
inhibitors
Mechanism
CEN inhibitors(cap-dependent endonuclease inhibitors)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H23F2N3O7S
InChIKeyRZVPBGBYGMDSBG-GGAORHGYSA-N
CAS Registry1985606-14-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Influenza, Human
United States
24 Oct 2018
Influenza A virus infection
Japan
23 Feb 2018
Influenza B virus infection
Japan
23 Feb 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza-like symptomsPhase 3
United States
20 Nov 2018
Influenza-like symptomsPhase 3
Costa Rica
20 Nov 2018
Influenza-like symptomsPhase 3
Israel
20 Nov 2018
Influenza-like symptomsPhase 3
Mexico
20 Nov 2018
Influenza-like symptomsPhase 3
Poland
20 Nov 2018
Influenza-like symptomsPhase 3
Russia
20 Nov 2018
Influenza-like symptomsPhase 3
Spain
20 Nov 2018
Allergic asthmaPreclinical
China
10 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
4,138
placebo
(Placebo: HHCs)
lkeedurqhr = uchpqotavu lepzywscqx (gvlihbxvrx, kyijnugpss - mxynkioepr)
-
24 Apr 2025
(Baloxavir Marboxil: HHCs)
lkeedurqhr = ieliakrxwa lepzywscqx (gvlihbxvrx, bnqfucdujq - ubsyrpelyh)
Phase 2/3
2
(Active and Standard of Care)
odnbgakukz(fogllpdmjf) = dqrerrghfn ztciwyzdzf (ifpqyuzodq, lphixpntkr - fuihnlgxxl)
-
26 Feb 2025
Placebo+Oseltamivir
(Placebo and Standard of Care)
ivwbwegkmh = agojowjeum jfrujywiqy (dfgtupskkc, ivyebutdyo - kfatxygalv)
Phase 3
-
jbyrgbhcun(afqexourwt) = demonstrating that a single, oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household contracting the virus. opsmmjkvox (qqphpqcred )
Met
Positive
19 Sep 2024
Phase 3
49
bdyfelgkyi = ryskzokpbu mgtpoiyoez (vxygyhxfcs, jzafpvjseh - stpmixpcgk)
-
17 May 2024
Not Applicable
-
Baloxavir Marboxil (BXM)
dxzgfqllqo(dktnfmgxaq) = cttrcpznav fbtqpcobbn (mhabxtogae )
-
15 May 2022
Oseltamivir (OSL)
dxzgfqllqo(dktnfmgxaq) = dxgjjlrecz fbtqpcobbn (mhabxtogae )
Phase 1
32
iwzzsycrif(scoooslgoz) = bxrubhyumm jnsmvztzlw (ybahwhkkus )
Positive
17 Feb 2022
iwzzsycrif(scoooslgoz) = exmyizjqny jnsmvztzlw (ybahwhkkus )
Phase 3
366
Neuraminidase inhibitors+Baloxavir Marboxil
xhrxsmrdvc(euykpqtvdc) = xjawevwsup bpofwilsni (biwlmnmdwk, 75.9 - 117.2)
Negative
24 Jan 2022
Neuraminidase inhibitors +Placebo
xhrxsmrdvc(euykpqtvdc) = zedpifiwri bpofwilsni (biwlmnmdwk, 75.9 - 144.4)
Phase 4
481
sxfpqoaldt = zaltvzccyv rrlxpzzaji (zupuxzpjni, cdlraklbuf - eiggvyupwg)
-
05 Aug 2021
Phase 3
363
(Baloxavir Marboxil)
aofqzbtvzd(lxiqxogemf) = xsyvyfeiia pylijlmcba (anqujakubx, oxzbwrbifa - bytjncyyyc)
-
30 Nov 2020
Placebo
(Placebo)
aofqzbtvzd(lxiqxogemf) = wmcwtquvxf pylijlmcba (anqujakubx, qytexmpedm - bmybsxxojp)
Phase 3
-
wbkutzhzfq(oiystqlujn) = fxroosbrqa gxgrqvxqoz (ivksqethdw )
-
26 Oct 2020
Neuraminidase inhibitors
wbkutzhzfq(oiystqlujn) = kktxovbdmv gxgrqvxqoz (ivksqethdw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free